Geron to Present at the Stifel 2021 Virtual Healthcare Conference

Rhea-AI Summary

Geron Corporation (Nasdaq: GERN), a biopharmaceutical firm specializing in hematologic malignancies, announced that Dr. John A. Scarlett will present a company overview at the Stifel 2021 Virtual Healthcare Conference on November 16, 2021, at 2:40 p.m. ET. The presentation will be available via a live webcast on Geron's Investor Relations website and archived for 30 days thereafter. Geron is currently conducting two Phase 3 trials for its telomerase inhibitor, imetelstat, targeting lower risk myelodysplastic syndromes and refractory myelofibrosis.

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, will present a company overview at the Stifel 2021 Virtual Healthcare Conference on Tuesday, November 16, 2021 at 2:40 p.m. ET.

A live webcast of the presentation will be available through the Investor Relations section of Geron’s website under Events. Following the presentation, the webcast will be archived and available for replay for a period of 30 days.

About Geron

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis. For more information about Geron, visit www.geron.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211112005451/en/

Olivia Bloom

Chief Financial Officer

investor@geron.com

media@geron.com

Source: Geron Corporation

FAQ

When is Geron's presentation at the Stifel 2021 Virtual Healthcare Conference?

Geron's presentation is on November 16, 2021, at 2:40 p.m. ET.

How can I watch Geron's presentation at the Stifel Conference?

The presentation can be viewed via a live webcast on Geron's Investor Relations website.

What clinical trials is Geron currently conducting?

Geron is conducting two Phase 3 clinical trials: IMerge for lower risk myelodysplastic syndromes and IMpactMF for refractory myelofibrosis.

What is Geron's main product focus?

Geron's primary focus is the development of imetelstat, a first-in-class telomerase inhibitor for hematologic malignancies.